Exavir Therapeutics
PrivateLast Round
Grant
Aug 22, 2023
Total Funding Raised
$7M
Company Overview
Exavir Therapeutics operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Grant round in August 2023.
Exavir Therapeutics is a biotechnology company that develops ultra-long-acting nano-medicines for the treatment and prevention of chronic viral infections, including HIV.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Exavir Therapeutics Comparables
Compare Exavir Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Excision BioTherapeutics | 74% | |
| MedinCell S.A. | 70% | |
| DelSiTech | 70% |
For institutional investors. Book with your work email.
Exavir Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 22, 2023 | ||||
| Seed | May 23, 2022 |
For institutional investors. Book with your work email.
Exavir Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| AlleyCorp | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Monthly visitors increased 68% MoM.
- Jan 21, 2026
Monthly visitors increased 557% MoM, from 61 to 401.
For institutional investors. Book with your work email.
Exavir Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Exavir Therapeutics's valuation, stock price, and market status.
Is Exavir Therapeutics a public or private company?
Exavir Therapeutics is a private company.
What is the current stock price of Exavir Therapeutics?
Exavir Therapeutics is a private company, so its shares have no public market price. Caplight tracks Exavir Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Exavir Therapeutics worth (valuation)?
Valuation information for Exavir Therapeutics is not publicly available.
Can I buy Exavir Therapeutics stock?
Exavir Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Exavir Therapeutics's last funding round?
Exavir Therapeutics's most recent funding round was Grant on August 22, 2023.
Who are the main investors in Exavir Therapeutics?
Key investors in Exavir Therapeutics include AlleyCorp.
Will Exavir Therapeutics IPO soon?
No public IPO plans have been announced for Exavir Therapeutics.
How can I track Exavir Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Exavir Therapeutics's shares on secondary markets.